AGI Therapeutics records losses of €4.3m

IEX-listed gastrointestinal drug products company AGI Therapeutics has announced net losses of €4.3m.

AGI Therapeutics records losses of €4.3m

IEX-listed gastrointestinal drug products company AGI Therapeutics has announced net losses of €4.3m.

AGI was listed last year on the IEX Market in Dublin and on London's AIM market, raising gross proceeds of €42.5m.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited